Table 3.

Pharmacological treatments and radiotherapy in HER2 positive Breast Cancer Patients

	n (%)
Pharmacological treatment setting from diagnosis till end of data collection (cut-off point), n = 309
Neoadjuvant only	10 (3.2%)
Adjuvant only	134 (43.4%)
Metastatic only	46 (14.9%)
Neoadjuvant + Adjuvant + Metastatic	22 (7.1%)
Neoadjuvant + Adjuvant	74 (23.9%)
Adjuvant + Metastatic	19 (6.1%)
Neoadjuvant treatment regimens, n = 110
Neoadjuvant + Metastatic	4 (1.3%)
Hormonotherapy alone	3 (2.7%)
Chemotherapy alone	83 (75.5%)
Trastuzumab alone	7 (6.4%)
Chemotherapy + Trastuzumab	87 (79.1%)
Other regimens	2 (1.8%)
Adjuvant treatment regimens, n = 249
Hormonotherapy alone	140 (56.2%)
Chemotherapy alone	113 (45.4%)
Trastuzumab alone	96 (38.6%)
Chemotherapy + Trastuzumab	129 (51.8%)
Hormonotherapy + Trastuzumab	22 (8.8%)
Metastatic treatment regimens, n = 91
Hormonotherapy alone	41 (45.1%)
Chemotherapy alone	40 (44.0%)
Targeted therapy alone	36 (45.1%)
Chemotherapy + Targeted therapy	59 (64.8%)
Hormonotherapy + Targeted therapy	14 (15.4%)
Hormonotherapy + Chemotherapy + Targeted therapy	2 (3.3%)
Radiotherapy, n = 347
No	98 (28.2%)
Yes	249 (71.8%)